Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia. (Q50858984)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia. (English)

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Birgit Burkhardt

1

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

Deniz Yavuz

2

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

Martin Zimmermann

3

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

Jutta Schieferstein

4

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

Edita Kabickova

5

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

Andishe Attarbaschi

6

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

Jasmin Lisfeld

7

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

Alfred Reiter

8

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

Olga Makarova

9

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

Jennifer Worch

10

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

Bettina R Bonn

11

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

Christine Damm-Welk

12

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

publication date

4 July 2016

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

Annals of Hematology

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

95

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

1503-1512

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

9

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

Interindividual variability of response to rituximab: from biological origins to individualized therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

Effect of FCGR2A and FCGR3A variants on CLL outcome

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

The H/R FcγRIIA-131 polymorphism and survival in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: a study in a genetically mixed population

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

IVIG therapy: interfering with interferon-gamma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2731-X

21 January 2018

Identifiers

10.1007/S00277-016-2731-X

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/27376362

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50858984&oldid=1561126956"